These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27227380)

  • 1. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
    Blake JF; Burkard M; Chan J; Chen H; Chou KJ; Diaz D; Dudley DA; Gaudino JJ; Gould SE; Grina J; Hunsaker T; Liu L; Martinson M; Moreno D; Mueller L; Orr C; Pacheco P; Qin A; Rasor K; Ren L; Robarge K; Shahidi-Latham S; Stults J; Sullivan F; Wang W; Yin J; Zhou A; Belvin M; Merchant M; Moffat J; Schwarz JB
    J Med Chem; 2016 Jun; 59(12):5650-60. PubMed ID: 27227380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
    Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
    J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
    Ward RA; Anderton MJ; Bethel P; Breed J; Cook C; Davies EJ; Dobson A; Dong Z; Fairley G; Farrington P; Feron L; Flemington V; Gibbons FD; Graham MA; Greenwood R; Hanson L; Hopcroft P; Howells R; Hudson J; James M; Jones CD; Jones CR; Li Y; Lamont S; Lewis R; Lindsay N; McCabe J; McGuire T; Rawlins P; Roberts K; Sandin L; Simpson I; Swallow S; Tang J; Tomkinson G; Tonge M; Wang Z; Zhai B
    J Med Chem; 2019 Dec; 62(24):11004-11018. PubMed ID: 31710489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
    Lim J; Kelley EH; Methot JL; Zhou H; Petrocchi A; Chen H; Hill SE; Hinton MC; Hruza A; Jung JO; Maclean JK; Mansueto M; Naumov GN; Philippar U; Raut S; Spacciapoli P; Sun D; Siliphaivanh P
    J Med Chem; 2016 Jul; 59(13):6501-11. PubMed ID: 27329786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
    Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
    J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
    Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
    Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.
    Boga SB; Alhassan AB; Cooper AB; Doll R; Shih NY; Shipps G; Deng Y; Zhu H; Nan Y; Sun R; Zhu L; Desai J; Patel M; Muppalla K; Gao X; Wang J; Yao X; Kelly J; Gudipati S; Paliwal S; Tsui HC; Wang T; Sherborne B; Xiao L; Hruza A; Buevich A; Zhang LK; Hesk D; Samatar AA; Carr D; Long B; Black S; Dayananth P; Windsor W; Kirschmeier P; Bishop R
    Bioorg Med Chem Lett; 2018 Jun; 28(11):2029-2034. PubMed ID: 29748051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
    Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
    Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2).
    Li L; Liu F; Jin N; Tang S; Chen Z; Yang X; Ding J; Geng M; Jiang L; Huang M; Cao J
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2600-4. PubMed ID: 27106711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
    Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
    Velaparthi U; Wittman M; Liu P; Carboni JM; Lee FY; Attar R; Balimane P; Clarke W; Sinz MW; Hurlburt W; Patel K; Discenza L; Kim S; Gottardis M; Greer A; Li A; Saulnier M; Yang Z; Zimmermann K; Trainor G; Vyas D
    J Med Chem; 2008 Oct; 51(19):5897-900. PubMed ID: 18763755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
    Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
    Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
    J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
    Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers.
    Zhao P; Zhuang L; Wang X; Huang S; Wu H; Zhou Y; Yan Y; Zhang F; Shen R; Li J; Liu S; Zhang R; Dong P; Mao Y; Fan Y; He C; Sun J; Zhang L; Hu Q; Wan H; Feng J; Bai C; He F; Tao W
    Eur J Med Chem; 2022 Jan; 228():114040. PubMed ID: 34906761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
    Fraser C; Dawson JC; Dowling R; Houston DR; Weiss JT; Munro AF; Muir M; Harrington L; Webster SP; Frame MC; Brunton VG; Patton EE; Carragher NO; Unciti-Broceta A
    J Med Chem; 2016 May; 59(10):4697-710. PubMed ID: 27115835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.